Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2026-03-26 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
关于注销部分募集资金专项账户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the cancellation (注销) of a portion of the company's special fundraising accounts. It details the background of the fundraising, the management of the funds, and the completion of the account cancellation process. The document is relatively short (1522 characters) and focuses on the status and administrative update of fundraising accounts rather than presenting financial statements or detailed financial data. It does not contain comprehensive financial results or analysis, nor is it a report or presentation. This fits the category of a Capital/Financing Update (CAP), as it provides an update on the company's fundraising activities and capital management.
2026-03-26 Chinese
第六届董事会第二十七次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 27th meeting of the 6th Board of Directors of Beijing Northland Biotechnology Co., Ltd. It details the meeting date, attendance, agenda items, and voting results. The content focuses on board decisions, specifically about the postponement of a fundraising project, and includes references to compliance with company law and internal procedures. There is no financial data, earnings information, or detailed report content. The document is clearly a Board/Management Information announcement about board meeting resolutions and decisions, not a full report or financial statement.
2026-03-26 Chinese
部分募投项目延期公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Northland Biotech Co., Ltd. regarding the delay of certain fundraising investment projects. It details the use of funds raised through a share issuance, the progress and delays in project implementation, and the company's decision to extend the project completion date. It includes financial figures related to fundraising and usage but does not contain comprehensive financial statements or detailed financial performance data. The document also references board resolutions approving the delay. The content focuses on fundraising project updates and capital usage rather than full financial results or audit information. Given the focus on fundraising and capital project updates, this fits best under Capital/Financing Update (CAP). The document length is 3066 characters, which is relatively short but contains substantive information about capital usage and project delays, not just a brief announcement or report publication. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2026-03-26 Chinese
关于子公司酒石酸溴莫尼定滴眼液获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing Northland Biotechnology Co., Ltd. regarding its subsidiary receiving approval from the National Medical Products Administration for clinical trials of a pharmaceutical product. It includes details about the clinical trial approval, product specifications, and risk warnings. The document is short (891 characters) and serves as a regulatory announcement about a clinical trial approval, not a financial report or detailed management discussion. It does not contain financial data, earnings, or governance changes. It is a regulatory announcement related to drug development progress, fitting best under Regulatory Filings (RNS).
2026-03-24 Chinese
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about the company's use of idle raised funds for cash management, including specifics on investment products, amounts, dates, risk controls, and compliance with stock exchange disclosure rules. It is not a full financial report, audit, or earnings release, nor is it a brief summary or presentation. The document is longer than 4,000 characters and contains substantive information about financing activities related to cash management of raised funds. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. There is no indication that this is merely an announcement of a report publication or a regulatory filing. Therefore, the best classification is CAP with high confidence.
2026-03-08 Chinese
关于使用部分闲置自有资金委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Beijing Northland Biotechnology Co., Ltd. regarding the progress of using part of its idle own funds for entrusted financial management. It includes specifics about the amounts, types of financial products purchased, expected yields, investment periods, and risk controls. The document references a prior board meeting resolution authorizing the use of idle funds for financial products and discloses ongoing and matured entrusted financial products. It is a regulatory disclosure about the company's financing activities related to entrusted financial management, not a financial report, earnings release, or management discussion. The document is longer than 5,000 characters and contains substantive details about capital usage and financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2026-03-08 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.